This post is written by Osama Hamdy, M.D.,Medical Director, Obesity Clinical Program, Director of Inpatient Diabetes Management at Joslin Diabetes Center, Assistant Professor of Medicine at Harvard Medical School.
Diabetes is the only harmful side effect linked to statins, the study found, with 3 percent of people on statins being newly diagnosed with diabetes, compared with 2.4 percent of people taking placebos. That means that for every five new cases of diabetes in people taking statins, one is caused by the drug.
A change in thinking about the ways type 2 diabetes evolves indirectly opened the door to considering new ways of thinking about how type 1 diabetes behaves. That shift led to considering whether that door swung both ways and if type 1 diabetics might benefit from treatments designed to treat type 2 diabetes.
The drugs in question, called GLP-1 medicines, help spur insulin production after meals. Nine are approved in Europe and seven in the U.S., including include Merck’s Januvia and Janumet, Novo Nordisk’s Victoza and Bristol-Myers Squibb’s Byetta and Bydureon.
The investigational type 2 diabetes drug empagliflozin won’t win the FDA’s approval until “previously observed deficiencies” at a manufacturing plant are fixed, the drug’s sponsors said last week.
The pre-filled, single-use pen injector eliminates the need for patients to transfer the medication between a vial and a syringe. It contains the same formulation and dose as the original Bydureon single-dose tray, providing the same continuous release of exenatide.
The U.S. Food and Drug Administration reports that its review of various animal and human studies does not show a link between GLP-1 drugs used to treat type 2 diabetes and pancreatic maladies, including acute pancreatitis and pancreatic cancer.
Do you have Type 1 diabetes? If so, your relatives may be interested in an actively recruiting TrialNet study that is testing whether oral insulin can prevent or delay the development of Type 1 in people who are at increased risk of the condition.
A total of 182 new drugs to treat diabetes or diabetes-related conditions are currently in clinical trials or undergoing review by the U.S. Food and Drug Administration, according to a report just published by the Pharmaceutical Research and Manufacturers of America (PhRMA).
This study was conducted using data from The Health Improvement Network (THIN), an electronic medical records database used in the UK. The database contains information for >10 million patients, making it ideal for rarer outcomes such as bladder cancer.
Corticosteroids, or steroids for short, are used to reduce inflammation and suppress the immune system. They are often a last resort for a wide variety of conditions, in everything from asthma to allergy attacks to arthritis and ulcerative colitis.
A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system.
Since type 1 diabetics are constantly dealing all their lives with the issue of glucose release after meals, at night, and whenever from our livers, why aren’t we given metformin to control this process as a standard of care? Why is it that metformin is only given to type 2 diabetics when type 1s are […]
NM504 is designed to improve glucose tolerance and other metabolic parameters in patients with diabetes by shifting the gastrointestinal microbiome–the micro-organisms that inhabit the human body.
Oramed has submitted a protocol to the FDA to initiate a Phase 2a trial of its orally ingestible insulin capsule, ORMD 0801, for type 1 diabetes. The double-blind, randomized, placebo controlled, seven-day study design will be carried out at an inpatient setting on twenty-four type 1 diabetic patients
Statins are safe, well-studied drugs. But even they can sometimes have risks. Many people have used statins for a long time with absolutely no side effects. Lovastatin (Mevacor®) was the first statin approved more than 25 years ago.
In a safety alert published by the FDA on February 11th, the administration says it has requested clinical trial data from the maker of saxagliptin to investigate the possible association between use of the drug and heart failure.
If more insulin isn’t the answer to better control, what might be? Some researchers believe it might be dapagliflozin, a new drug that can prevent glucose reabsorption into the kidneys, lower A1c and reduce insulin doses simultaneously, according to a recently completed pilot Phase IIa trial.
The cream, which has been tested on mice in two trials, is designed to replenish GDNF, a group of cells that play a role in stimulating nerve growth. For those with small-fiber neuropathy–which reveals itself through pain and tingling in the extremities, usually the feet–the cells are lost through the degeneration of nerve endings.
You might have already heard of the first SGLT2 drug approved by the FDA. It’s called Invokana, and it arrived in the United States last year. Terminology aside, this class of drugs seems to represent a conspicuous advance in treatment for type 2s. And it’s all because they work in a distinctly different way than […]